Tadalafil Tablet
Product Images NDC 68071-3545

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3545 3)

Label for Tadalafil 5 mg tablets by NuCare Pharmaceuticals, Inc. The package contains 30 tablets. The label includes the National Drug Code (NDC) 68071-3545-3 and states 'Rx Only'. It also provides manufacturer information, a warning to keep out of reach of children, and storage instructions at controlled temperature 68-77°F. Additional lot, serial, and expiration details appear on smaller sections of the label.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, a human prescription drug. The diagram shows the molecular layout of tadalafil, including rings and functional groups, consistent with its known chemical formula.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing blood pressure changes over time comparing tadalafil to placebo. The charts illustrate differences in standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, measured in mmHg over a time period up to 96 hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This figure presents two line graphs comparing the effect of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure (mmHg) over 24 hours post-dose. The upper graph shows standing systolic blood pressure changes, and the lower graph shows supine systolic blood pressure changes, with time post-dose in hours on the x-axis and blood pressure change on the y-axis.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph showing the effect of 20 mg tadalafil versus placebo, both combined with 8 mg doxazosin, on systolic blood pressure (mmHg) over 12 hours after administration at two different times (08:00 and 20:00). The graph tracks changes in systolic blood pressure over time for each treatment condition.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) after single doses of 5 mg and 20 mg tadalafil and once-daily 5 mg tadalafil following 5 consecutive days of administration. The graph shows time on the x-axis up to 120 hours and plasma concentration on the y-axis up to 500 µg/L, illustrating concentration changes and variability with error bars for each dosing regimen.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period between tadalafil tablets 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in IPSS score. The tadalafil group shows a greater improvement compared to placebo, with statistically significant difference noted at 12 weeks (p<0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line chart depicting change from baseline in IPSS Total Score over 12 weeks comparing Tadalafil tablets 5 mg and placebo. The x-axis shows duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows change in IPSS score. Tadalafil shows a greater decrease over time than placebo, with significant differences at certain points indicated by an asterisk (p<0.01).*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph depicting the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the mean change from baseline, ranging from 0 to -7. Two lines plot the data points for each treatment group over time, with annotations indicating statistical significance at various time points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing change from baseline in IPSS Total Score over 12 weeks between tadalafil tablets 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS Total Score, with results indicating greater symptom improvement for tadalafil versus placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.